| Literature DB >> 31413807 |
Katie E Archer1, Emily E Reid1, Manami Shizuka1, James Woods1, Luke Harris1, Erin K Maloney1, Laura M Bartle1, Olga Ab1, Alan Wilhelm1, Yulius Setiady1, Jose F Ponte1, Rajeeva Singh1, Thomas A Keating1, Ravi V J Chari1, Michael L Miller1.
Abstract
Indolinobenzodiazepine DNA alkylators (IGNs) are the cytotoxic payloads in antibody-drug conjugates (ADCs) currently undergoing Phase I clinical evaluation (IMGN779, IMGN632, and TAK164). These ADCs possess linkers that have been incorporated into a central substituted phenyl spacer. Here, we present an alternative strategy for the IGNs, linking through a carbamate at the readily available N-10 amine present in the monoimine containing dimer. As a result, we have designed a series of N-10 linked IGN ADCs with a wide range of in vitro potency and tolerability, which may allow us to better match an IGN with a particular target based on the potential dosing needs.Entities:
Year: 2019 PMID: 31413807 PMCID: PMC6691681 DOI: 10.1021/acsmedchemlett.9b00254
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345